|Name of Company||Country of Origin/ Exchange Traded||Sector||Stock Price|
|VECTURA GROUP PLC||UK/
|Healthcare – Drug Manufacturers – Drug Manufacturers – Major||GBP0.78|
|@ 25 Sep 2018|
|COMPANY PROFILE||Vectura Group plc is a respiratory product development company. It is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use.
Vectura Group PLC is a major drug manufacturing company. The company’s pharmaceutical business consists of the research, development, and commercialization of pharmaceutical products. The vast majority of the company’s revenue and losses before taxation originate in the United Kingdom and Germany. The company utilizes committed pipeline programs combining novel and known drug/device combinations while exploring opportunities to further leverage existing partnerships. Vectura’s product development process includes formulation, device design, and device commercialization.
|Stock Valuation Below|
|Price to Cash Flow is an alternative method to value shares. This is because accounting profits can be subject to manipulation. Therefore, some investors prefer to value a company based on cash flows generated by the operating activities of the company. It also acts as a reality check to valuation measures such as Price to Earnings and Price to Sales. If a company generates high profits and sales but not operating cash flows, it could be heading for trouble because it is cash that pays the operating expenses. However, the Price to Cash Flow ratio of most firms are volatile and should not be used in isolation to determine the valuation of the stock.|
|At the price of GBP0.78 as at 25 Sep 2018, Vectura Group Plc is trading at a Price to Cash Flow Ratio of 32.7 times last 12 months cash flow. This is a 34.6% premium to current fair Price to Cash Flow Ratio of 24.3 times.|
|Is the stock overvalued? One should not just look at one indicator to determine the fair value of a stock.|
|ProThinker believes in using a combination of valuation methods to decide whether a stock is over or undervalued? The five ratios we use are Price to Earnings, Price to Sales, Price to Cash Flow, Price to Book and Dividend Yield. We use multiple methods to value a stock because each has its benefits as well as shortcomings. Price to Earnings and Price to Cash Flow Ratios relate stock price to profitability but are meaningless when the comany has negative earnings or cash flows. Price to Sales Ratio is more stable because sales are never negative. However, this does not tell us whether the company is able to sell profitably. Price to Book Ratio gives us an indication as to how much we are paying for the company’s assets but it is not directly related to the company’s profitability. Dividend Yield cannot be used for companies that are paying little to no dividends.|
|While it is important to value stocks based on multiple valuation methods, this often leads to differing views on valuation. One indicator may suggest that a stock is overvalued while another suggest that it is undervalued. This does not help an investor who needs to make a definite decision whether to buy, hold or sell the stock. That is why we advocate the use of a Composite Valuation Indicator, which is derived from the best combination of the five indicators above. A Composite Valuation Indicator will give you ONE conclusion on whether a stock is under or over valued.|
|To find out more about our valuation methodology, click here.|
|Source of Data: Company description, historical financial statements data and price data are from gurufocus.com or moneycontrol.com. Estimates are from marketscreener.com – Thomson Reuters.|
|Disclaimer: This report is for information purposes only and should not be considered a solicitation to buy or sell any security. Neither ProThinker nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without the express written consent of ProThinker. Copyright(c) 2018. All rights reserved.|